Clinical and pharmacovigilance safety evaluation of LUXTURNA <sup>®</sup> (voretigene neparvovec-rzyl)
LUXTURNA<sup>®</sup> provides meaningful and durable visual benefits for patients with RPE65-related disease, but long-term monitoring is essential to address its emerging ocular safety profile. Our data represent the first comprehensive pharmacovigilance review of LUXTURNA<sup>®</sup>, providing critical insights for clinical practice and post-marketing surveillance.
Authors
- Simon Kaja (ORCID: https://orcid.org/0000-0001-6878-521X)
- W. Keith Jones
- Djamilla Simoens
- Varun Shravah
Institutions
- Loyola University Chicago (US)
- Loyola Medicine (US)
Publication Details
- Journal
- Cutaneous and Ocular Toxicology
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1080/15569527.2025.2573463
- Citations
- 1
- Primary Topic
- Biotin and Related Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.15